An antibody-drug conjugate targeting Trop-2 that delivers the topoisomerase I inhibitor SN-38 to induce DNA damage and cytotoxicity.
Humanized anti-TROP2 monoclonal antibody linked to SN-38. Upon TROP2 binding and internalization, the linker is cleaved to release SN-38, which inhibits topoisomerase I, stabilizes TOP1-DNA complexes, causes DNA breaks, blocks DNA replication, and induces apoptosis.
NO
INDIRECT
The ADC binds TROP2 (not topoisomerase I), is internalized, and releases SN-38, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I expression alone does not make cells directly targeted or killed.
An investigational intravenous anticancer agent; the registry does not specify its drug class or precise mechanism of action.
An anti–nectin-4 (PVRL4) IgG1 antibody–drug conjugate. The antibody binds nectin-4 on tumor cells and is internalized; a cleavable linker then releases a topoisomerase-1 inhibitor payload that blocks Topo I–mediated DNA replication, leading to cell-cycle arrest and apoptosis in nectin-4–expressing cancer cells.
YES
DIRECT
The anti–nectin-4 antibody-drug conjugate binds Nectin-4 on target cells, is internalized, and a cleavable linker releases a topoisomerase-1 inhibitor that blocks DNA replication, leading to cell-cycle arrest and apoptosis of Nectin-4–expressing cells.
An investigational intravenous anticancer agent; the registry does not specify its drug class or precise mechanism of action.
An anti–nectin-4 (PVRL4) IgG1 antibody–drug conjugate. The antibody binds nectin-4 on tumor cells and is internalized; a cleavable linker then releases a topoisomerase-1 inhibitor payload that blocks Topo I–mediated DNA replication, leading to cell-cycle arrest and apoptosis in nectin-4–expressing cancer cells.
NO
INDIRECT
SHR-A2102 binds nectin-4 on tumor cells, is internalized, and releases a topoisomerase-1 inhibitor that blocks DNA replication and induces apoptosis. Topoisomerase I is only the intracellular payload target; its expression alone does not make cells the targets of killing.
An intravenous monoclonal antibody that binds TRBV9 on the T-cell receptor beta chain to selectively target TRBV9-expressing T lymphocytes, aiming to modulate or deplete these cells and reduce TCR-driven pathogenic responses in axial spondyloarthritis.
Monoclonal antibody that binds the TRBV9 region of the T-cell receptor beta chain to selectively target TRBV9-expressing T lymphocytes, leading to modulation or depletion of these cells and reduction of pathogenic TCR-driven responses in axial spondyloarthritis.
YES
DIRECT
Binding to TRBV9 on T cells engages Fc-mediated effector functions (ADCC/CDC), leading to depletion/killing of TRBV9+ T lymphocytes.
A Trop-2–directed antibody–drug conjugate that delivers SN-38 (a topoisomerase I inhibitor) to tumor cells, causing DNA damage and a bystander effect.
Humanized anti–Trop-2 monoclonal antibody linked to SN-38; binds Trop-2 on tumor cells, is internalized and cleaved to release SN-38, a topoisomerase I inhibitor that stabilizes topoisomerase I–DNA complexes, causing DNA damage, replication arrest, apoptosis, and a bystander effect.
YES
DIRECT
The anti–TROP-2 ADC binds TROP-2 on target cells, is internalized, and releases SN-38 (a topoisomerase I inhibitor) intracellularly, causing DNA damage, replication arrest, and apoptosis; the payload can also cause a bystander effect.